Drug intelligence / Profile preview

SLAB51

Development stage: Unknown
Lead developer: ExeGi Pharma
Modality: Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

SLAB51 is a high-potency, multi-strain probiotic formulation developed by Professor Claudio De Simone. It consists of eight specific live bacterial strains: Streptococcus thermophilus (DSM 32245), Bifidobacterium animalis subsp. lactis (DSM 32246 and DSM 32247), Lactobacillus acidophilus (DSM 32241), Lactobacillus helveticus (DSM 32242), Lactobacillus paracasei (DSM 32243), Lactobacillus plantarum (DSM 32244), and Lactobacillus brevis (DSM 27961). SLAB51 is designed to support gastrointestinal health, modulate the gut-brain axis, and reduce oxidative stress and inflammation. It has been investigated in preclinical models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as in clinical studies for enhancing oxygenation and mitigating hypoxic symptoms.

Brand names: AgimixxAthlemixxO2 BoosterO-2 BoosterO 2 BoosterO2 Booster FreshO-2 Booster FreshO 2 Booster FreshOxxySlabSivoMixxSivoySivoy51Sivoy-51Sivoy 51Visbiome Vet Constipation Care
Other names: Slab51Slab-51Slab 51

Beyond the preview

Go deeper on SLAB51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLAB51.